Cara Therapeutics, Inc. (LON:0HTC)

Market Cap	17.97M
Revenue (ttm)	6.48M
Net Income (ttm)	-71.27M
Shares Out	n/a
EPS (ttm)	-15.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4
Average Volume	253
Open	5.15
Previous Close	5.00
Day's Range	5.07 - 5.11
52-Week Range	0.50 - 5.82
Beta	n/a
RSI	51.80
Earnings Date	Mar 3, 2025

About Cara Therapeutics

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruish...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2004
• Employees: 55
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HTC

Financial Performance

In 2023, Cara Therapeutics's revenue was $20.97 million, a decrease of -49.92% compared to the previous year's $41.87 million. Losses were -$118.51 million, 38.7% more than in 2022.

Financial numbers in USD